Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
AssigneeBaxalta Incorporated
InventorsBernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
Life of this patent
Estimating the term…
Abstract
The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
Claims6
A method of treating a disease in which a patient has a supranormal vWF content or an increased level of high-molecular weight vWF, wherein the method comprises administering a pharmaceutical composition comprising an effective dose of an isolated polypeptide that has vWF protease activity and comprises a peptide chain that has a molecular weight from about 180 kD to about 120 kD as determined by SDS-PAGE under reducing conditions and comprises the amino acid sequence AAGGILHLELLV (SEQ ID NO:1), and wherein the polypeptide is purified from human plasma or is encoded by a nucleic acid present in a human cDNA library.
Dependencies are inferred from the claim text.